Что скрывают противозачаточные. Как вернуть контроль над своими гормонами за 30 дней - Джолин Брайтен

Fang, X., et al. “Dose-Response Relationship Between Dietary Magnesium Intake and Cardiovascular Mortality: A Systemic Review and Dose-Based Meta-Regression Analysis of Prospective Studies”. Journal of Trace Elements in Medicine and Biology 38 (2016): 64–73.

Glintborg, D. “Increased Thrombin Generation in Women with Polycystic Ovary Syndrome: A Pilot Study on the Effect of Metformin and Oral Contraceptives”. Metabolism 64, no. 10 (2015): 1272–78.

Greenlund, K. J., et al. “Associations of Oral Contraceptive Use with Serum Lipids and Lipoproteins in Young Women: The Bogalusa Heart Study”. Annals of Epidemiology 7, no. 8 (1997): 561–67.

Haarala, A., et al. “Use of Combined Oral Contraceptives Alters Metabolic Determinants and Genetic Regulation of C-Reactive Protein. The Cardiovascular Risk in Young Finns Study”. Scandinavian Journal of Clinical and Laboratory Investigation 69, no. 2 (2009): 168–74.

Hankinson, S. E., et al. “A Prospective Study of Oral Contraceptive Use and Risk of Breast Cancer (Nurses’ Health Study, United States)”. Cancer Causes and Control 8, no. 1 (1997): 65–72.

Houston, M. “The Role of Magnesium in Hypertension and Cardiovascular Disease”. Journal of Clinical Hypertension 13, no. 11 (2011): 843–47.

Kalkhof, R. K. “Effects of Oral Contraceptive Agents and Sex Steroids on Carbohydrate Metabolism”. Annual Review of Medicine 23 (1972): 429–38.

Kemmeren, J. M., et al. “Effect of Second- and Third-Generation Oral Contraceptives on the Protein C System in the Absence or Presence of the Factor V Leiden Mutation: A Randomized Trial”. Blood 103, no. 3 (2004): 927–33.

Kemmeren, J. M., et al. “Effects of Second- and Third-Generation Oral Contraceptives and Their Respective Progestagens on the Coagulation System in the Absence or Presence of the Factor V Leiden Mutation”. Thrombosis and Haemostasis 87, no. 2 (2002): 199–205.

Kim, Sung-Woo, et al. “Long-Term Effects of Oral Contraceptives on the Prevalence of Diabetes in Post-menopausal Women: 2007–2012 KNHANES”. Endocrine 53, no. 3 (2016): 816–22.

Kjos, S. L., et al. “Contraception and the Risk of Type 2 Diabetes Mellitus in Latina Women with Prior Gestational Diabetes Mellitus”. JAMA 280, no. 6 (1998): 533.

Krauss, R. M., et al. “The Metabolic Impact of Oral Contraceptives”. American Journal of Obstetrics and Gynecology 167, no. 4, pt. 2 (1992): 1177–84.

Kuhl, H. “Hormonal Contraception and Substitution Therapy: The Importance of Progestogen for Cardiovascular Diseases”. [In German.] Geburtshilfe und Frauenheilkunde 52, no. 11 (1992): 653–62.

Larivée, N., et al. “Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters”. Drug Safety 40, no. 7 (2017): 583–96.

Lizarelli, P. M., et al. “Both a Combined Oral Contraceptive and Depot Medroxyprogesterone Acetate Impair Endothelial Function in Young Women”. Contraception 79, no. 1 (2009): 35–40.

Lobo, R. A., et al. “The Importance of Diagnosing the Polycystic Ovary Syndrome”. Annals of Internal Medicine 132, no. 12 (2000): 989–93.

Lydic, M. L., et al. “Chromium Picolinate Improves Insulin Sensitivity in Obese Subjects with Polycystic Ovary Syndrome”. Fertility and Sterility 86, no. 1 (2006): 243–46.

Macik, B. G., et al. “Thrombophilia: What’s a Practitioner to Do?” Hematology, American Society of Hematology Education Program (2001): 322–38. http://asheducationbook.hematologylibrary.org/content/2001/1/322.full.pdf.

Marchbanks, P. A., et al. “Oral Contraceptives and the Risk of Breast Cancer”. New England Journal of Medicine 346 (2002): 2025–32.

Martinelli, I., et al. “High Risk of Cerebral-Vein Thrombosis in Carriers of a Prothrombin-Gene Mutation and in Users of Oral Contraceptives”. New England Journal of Medicine 338, no. 25 (1998): 1793–97.

Martinelli, I., et al. “Hyperhomocysteinemia in Cerebral Vein Thrombosis”. Blood 102, no. 4 (2003): 1363–66.

Martinelli, I., et al. “Interaction Between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis”. Arteriosclerosis, Thrombosis, and Vascular Biology 19, no. 3 (1999): 700–3.

Mavropoulos, J. C., et al. “The Effects of a Low-Carbohydrate, Ketogenic Diet on the Polycystic Ovary Syndrome: A Pilot Study”. Nutrition and Metabolism 2 (2005): 35.

Merki-Feld, G. S. “Effect of Combined Hormonal Contraceptives on the Vascular Endothelium and New Cardiovascular Risk Parameters”. [In German.] Therapeutische Umschau 66, no. 2 (2009): 89–92.

Middeldorp, S., et al. “Effects on Coagulation of Levonorgestrel- and Desogestrel-Containing Low Dose Oral Contraceptives: A Cross-Over Study”. Thrombosis and Haemostasis 84, no. 1 (2000): 4–8.

Moghadam, A. M., et al. “Efficacy of Omega-3 Fatty Acid Supplementation on Serum Levels of Tumor Necrosis Factor-Alpha, C-Reactive Protein and Interleukin-2 in Type 2 Diabetes Mellitus Patients”. Singapore Medical Journal 53, no. 9 (2012): 615–19.

Mohllajee, A. P., et al. “Does Use of Hormonal Contraceptives Among Women with Thrombogenic Mutations Increase Their Risk of Venous Thromboembolism? A Systematic Review”. Contraception 73, no. 2 (2006): 166–78.

Moreno, V., et al. “Effect of Oral Contraceptives on Risk of Cervical Cancer in Women with Human Papillomavirus Infection: The IARC Multicentric Case-Control Study”. Lancet 359, no. 9312 (2002): 1085–92.

Murray, E. K. I., et al. “Thromboelastographic Identifies Cyclic Haemostatic Variations in Healthy Women Using Oral Contraceptives”. Thrombosis Research 136, no. 5 (2015): 1022–26.

Nestler, J. E., et al. “Ovulatory and Metabolic Effects of D-chiro-inositol in the Polycystic Ovary Syndrome”. New England Journal of Medicine 340, no. 17 (1999): 1314–20.

Nightingale, A. L., et al. “The Effects of Age, Body Mass Index, Smoking, and General Health on the Risk of Venous Thromboembolism in Users of Combined Oral Contraceptives”. European Journal of Contraception and Reproductive Health Care 5, no. 4 (2000): 265–74.

Nordio, M., et al. “The Combined Therapy with Myo-inositol and D-chiro-inositol Reduces the Risk of Metabolic Disease in PCOS Overweight Patients Compared to Myo-inositol Supplementation Alone”. European Review for Medical and Pharmacological Sciences 16, no. 5 (2012): 575–81.

Oner, G., et al. “Clinical, Endocrine, and Metabolic Effects of Metformin vs. N-Acteylcytseine in Women with Polycystic Ovary Syndrome”. European Journal of Obstetrics, Gynecology, and Reproductive Biology 159, no. 1 (2011): 127–31.

“Oral – Contraceptive Use and the Risk of Breast Cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development”. New England Journal of Medicine 315, no. 7 (1986): 405–11.